Dermapharm Holding SE Increases Revenue and Exceeds EBITDA Guidance

Dermapharm Holding SE announced a 4.0% increase in consolidated revenue to EUR 1,180.8 million for 2024, mainly due to strong organic growth in the "Branded pharmaceuticals" segment. The company's unadjusted consolidated EBITDA rose by 10.2% to EUR 308.9 million, improving the margin to 26.2%. Adjusted consolidated EBITDA reached EUR 315.6 million, with adjustments significantly decreasing to EUR 6.7 million compared to 2023.

For 2025, Dermapharm anticipates further growth in EBITDA, supported by the German branded pharmaceuticals sector and international efforts. The "Parallel import business" saw revenue increase, although regulatory changes pressured earnings. In contrast, the "Other healthcare products" segment faced revenue and EBITDA declines due to a decrease in Arkopharma Group's revenue.

The management proposes a dividend of 90 cents per share for the previous financial year, with final figures for 2024 expected on 28 March 2025.